



S6 Fig. Impact of *PIK3CA* mutations on the invasive disease-free survival (iDFS) and overall survival (OS) of 210 human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with stage I-III and at least 5-year follow-up. Kaplan-Meier survival analysis; p-values calculated using a log-rank analysis. Estimated iDFS and OS by mutant status: iDFS (A) and OS (B) for patients with wild-type (WT) and mutant (MT) of *PIK3CA*; iDFS (C) and OS (D) for patients with WT, hotspot MT and non-hotspot MT of *PIK3CA*.